A Phase 3 interventional study of Bulevirtide in Chronic Hepatitis Delta, sponsored by Gilead Sciences. Completed at 19 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the efficacy of bulevirtide administered subcutaneously (SC) for 48 weeks at a dose of 2 mg or 10 mg once daily for treatment of chronic hepatitis delta (CHD) in comparison to delayed treatment.
The main goal of this study is to determine the effectiveness of bulevirtide in participants randomized to bulevirtide 2 mg or 10 mg once daily SC as compared to participants randomized to delayed treatment for 48 weeks. Treatment will continue through Week 144 (participants randomized to delayed treatment will change to bulevirtide 10 mg once daily SC after Week 48 through Week 144). All participants will be followed off-treatment for an additional 96 weeks.
43 studies on the registry are indexed under Hepatitis D, Chronic; 9 are open to participants now.
This study's enrollment of 150 is above the median of 46 across 30 interventional studies indexed under Hepatitis D, Chronic.
Browse Hepatitis D, Chronic studies →Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Inclusion criteria for females:
Exclusion Criteria:
Individuals receiving prohibited treatment at Screening cannot be included into the study unless this treatment is withdrawn prior to randomization.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After an observational period of 48 weeks, participants will receive treatment with bulevirtide 10 mg/day subcutaneously (SC) for 96 weeks and will be followed for up to 96 weeks (Up to Week 240).
Drug: Bulevirtide
Participants will receive bulevirtide 2 mg/day SC for 144 weeks and will be followed for up to 96 weeks (Up to Week 240).
Drug: Bulevirtide
Participants will receive bulevirtide 10 mg/day SC for 144 weeks and will be followed for up to 96 weeks (Up to Week 240).
Drug: Bulevirtide
Administered via SC injections
Also known as: Myrcludex B, Hepcludex®
Percentage of Participants With Combined Response at Week 48
Combined response was defined as fulfilment of two conditions simultaneously: Undetectable (\< lower limit of quantification (LLOQ, target not detected)) HDV RNA or decrease by ≥ 2 log10 IU/mL from baseline; and ALT normalization.
Time frame: Week 48
Percentage of Participants With Undetectable HDV RNA at Week 48
Undetectable HDV RNA at Week 48 means undetectable (\< LLOQ, target not detected) HDV RNA at Week 48.
Time frame: Week 48
Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48
ALT normalization was defined as an ALT value within the normal range, based on the central laboratories \[Russian sites: ≤ 31 U/L for females and ≤ 41 U/L for males; all other sites: ≤ 34 U/L for females and ≤ 49 U/L for males\])
Time frame: Week 48
Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 48
ANCOVA was used for analysis.
Time frame: Baseline (Baseline for Delayed Treatment/Bulevirtide 10 mg/day is reset at Week 48), Week 48
Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 96
Mixed model for repeated measurements (MMRM) was used for analysis.
Time frame: Baseline (Baseline for Delayed Treatment/Bulevirtide 10 mg/day is reset at Week 48), Week 96
Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 144
MMRM was used for analysis.
Time frame: Baseline, Week 144
Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 192
MMRM was used for analysis.
Time frame: Baseline (Baseline for Delayed Treatment/Bulevirtide 10 mg/day is reset at Week 48), Week 192
Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 240
MMRM was used for analysis.
Time frame: Baseline (Baseline for Delayed Treatment/Bulevirtide 10 mg/day is reset at Week 48), Week 240
Percentage of Participants With Undetectable HDV RNA 24 Weeks After Scheduled End of Treatment (Sustained Virological Response)
Undetectable HDV RNA 24 Weeks after Scheduled End of Treatment means undetectable (\< LLOQ, target not detected) HDV RNA at Week 168
Time frame: Week 168
Percentage of Participants With Undetectable HDV RNA 48 Weeks After Scheduled End of Treatment (Sustained Virological Response)
Undetectable HDV RNA 48 Weeks after Scheduled End of Treatment means undetectable (\< LLOQ, target not detected) HDV RNA at Week 192
Time frame: Week 192
Percentage of Participants Who Prematurely Discontinued Study Drug Due to an Adverse Event (AE) by Week 144
An AE was defined as any untoward medical occurrence in a participant administered study drug and which did not necessarily have a causal relationship with the study drug. An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to the study drug.
Time frame: Delayed Treatment/Bulevirtide 10 mg/day arm: Week 48 up to Week 144; Bulevirtide 2mg/day and 10 mg/day arms: First dose date up to Week 144
Participants were enrolled at study sites in Germany, Italy, Russia, and Sweden.
| Milestone | Delayed Treatment/Bulevirtide 10 mg/Day | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day |
|---|---|---|---|
| Started | 51 | 49 | 50 |
| Did not receive bulevirtide | 1 | 0 | 0 |
| Completed | 28 | 28 | 30 |
| Not completed | 23 | 21 | 20 |
| Withdrew: Withdrawal of consent | 8 | 8 | 9 |
| Withdrew: Physician decision | 5 | 4 | 1 |
| Withdrew: Pregnancy | 2 | 1 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Reason not specified | 3 | 3 | 5 |
| Withdrew: Adverse event | 2 | 1 | 4 |
| Withdrew: Progressive disease | 1 | 4 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
Combined response was defined as fulfilment of two conditions simultaneously: Undetectable (\< lower limit of quantification (LLOQ, target not detected)) HDV RNA or decrease by ≥ 2 log10 IU/mL from baseline; and ALT normalization.
| percentage of participants | Delayed Treatment | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day |
|---|---|---|---|
| Percentage of Participants With Combined Response at Week 48 | 2.0 (0.0 to 10.4) | 44.9 (30.7 to 59.8) | 48.0 (33.7 to 62.6) |
Undetectable HDV RNA at Week 48 means undetectable (\< LLOQ, target not detected) HDV RNA at Week 48.
| percentage of participants | Delayed Treatment | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day |
|---|---|---|---|
| Percentage of Participants With Undetectable HDV RNA at Week 48 | 0 (0.0 to 7.0) | 12.2 (4.6 to 24.8) | 20.0 (10.0 to 33.7) |
ALT normalization was defined as an ALT value within the normal range, based on the central laboratories \[Russian sites: ≤ 31 U/L for females and ≤ 41 U/L for males; all other sites: ≤ 34 U/L for females and ≤ 49 U/L for males\])
| percentage of participants | Delayed Treatment | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day |
|---|---|---|---|
| Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48 | 11.8 (4.4 to 23.9) | 51.0 (36.3 to 65.6) | 56.0 (41.3 to 70.0) |
ANCOVA was used for analysis.
| kPa | Delayed Treatment | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day | Delayed Treatment / /Bulevirtide 10 mg/Day |
|---|---|---|---|---|
| Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 48 | 0.87 (-0.79 to 2.53) | -3.06 (-4.67 to -1.45) | -3.16 (-4.88 to -1.43) | -3.36 (-4.60 to -2.12) |
Mixed model for repeated measurements (MMRM) was used for analysis.
| kPa | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day | Delayed Treatment/Bulevirtide 10 mg/Day |
|---|---|---|---|
| Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 96 | -4.31 (-5.54 to -3.08) | -4.88 (-6.11 to -3.65) | -4.20 (-5.41 to -2.98) |
MMRM was used for analysis.
| kPa | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day |
|---|---|---|
| Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 144 | -5.24 (-6.85 to -3.63) | -4.03 (-5.67 to -2.40) |
MMRM was used for analysis.
| kPa | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day | Delayed Treatment/Bulevirtide 10 mg/Day |
|---|---|---|---|
| Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 192 | -3.74 (-5.28 to -2.20) | -3.70 (-5.27 to -2.14) | -1.91 (-3.49 to -0.34) |
MMRM was used for analysis.
| kPa | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day | Delayed Treatment/ Bulevirtide 10 mg/Day |
|---|---|---|---|
| Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 240 | -1.20 (-3.71 to 1.31) | -3.31 (-5.78 to -0.84) | -3.59 (-6.14 to -1.04) |
Undetectable HDV RNA 24 Weeks after Scheduled End of Treatment means undetectable (\< LLOQ, target not detected) HDV RNA at Week 168
| percentage of participants | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day | Delayed Treatment/Bulevirtide 10 mg/Day |
|---|---|---|---|
| Percentage of Participants With Undetectable HDV RNA 24 Weeks After Scheduled End of Treatment (Sustained Virological Response) | 18.4 (8.8 to 32.0) | 26.0 (14.6 to 40.3) | 18.0 (8.6 to 31.4) |
Undetectable HDV RNA 48 Weeks after Scheduled End of Treatment means undetectable (\< LLOQ, target not detected) HDV RNA at Week 192
| percentage of participants | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day | Delayed Treatment/Bulevirtide 10 mg/Day |
|---|---|---|---|
| Percentage of Participants With Undetectable HDV RNA 48 Weeks After Scheduled End of Treatment (Sustained Virological Response) | 16.3 (7.3 to 29.7) | 24.0 (13.1 to 38.2) | 16.0 (7.2 to 29.1) |
An AE was defined as any untoward medical occurrence in a participant administered study drug and which did not necessarily have a causal relationship with the study drug. An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to the study drug.
| percentage of participants | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day | Delayed Treatment/Bulevirtide 10 mg/Day |
|---|---|---|---|
| Percentage of Participants Who Prematurely Discontinued Study Drug Due to an Adverse Event (AE) by Week 144 | 0 | 0 | 0 |
Collected over All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Delayed Treatment (Baseline to Week 48) | 0/51 (0%) | 1/51 (2%) | 30/51 (58.8%) |
| Bulevirtide 2 mg/Day (Baseline to Week 48) | 0/49 (0%) | 2/49 (4.1%) | 35/49 (71.4%) |
| Bulevirtide 10 mg/Day (Baseline to Week 48) | 0/50 (0%) | 1/50 (2%) | 41/50 (82%) |
| Bulevirtide 2 mg/Day (Baseline to Week 144) | 0/49 (0%) | 3/49 (6.1%) | 44/49 (89.8%) |
| Bulevirtide 10 mg/Day (Baseline to Week 144) | 0/50 (0%) | 6/50 (12%) | 46/50 (92%) |
| Delayed Treatment/Bulevirtide 10 mg/Day (Week 48 to Week 144) | 1/50 (2%) | 3/50 (6%) | 41/50 (82%) |
| Bulevirtide 2 mg/Day (After EOT (>Week 144 up to Week 240)) | 0/46 (0%) | 7/46 (15.2%) | 31/46 (67.4%) |
| Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) | 0/47 (0%) | 7/47 (14.9%) | 33/47 (70.2%) |
| Delayed Treatment/Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) | 0/49 (0%) | 8/49 (16.3%) | 34/49 (69.4%) |
| Event | Delayed Treatment (Baseline to Week 48) | Bulevirtide 2 mg/Day (Baseline to Week 48) | Bulevirtide 10 mg/Day (Baseline to Week 48) | Bulevirtide 2 mg/Day (Baseline to Week 144) | Bulevirtide 10 mg/Day (Baseline to Week 144) | Delayed Treatment/Bulevirtide 10 mg/Day (Week 48 to Week 144) | Bulevirtide 2 mg/Day (After EOT (>Week 144 up to Week 240)) | Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) | Delayed Treatment/Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis DInfections and infestations | 0/51 | 0/49 | 0/50 | 0/49 | 0/50 | 0/50 | 4/46 | 4/47 | 2/49 |
| Covid-19 pneumoniaInfections and infestations | 0/51 | 0/49 | 1/50 | 0/49 | 2/50 | 0/50 | 0/46 | 0/47 | 0/49 |
| AnaemiaBlood and lymphatic system disorders | 0/51 | 0/49 | 0/50 | 0/49 | 0/50 | 0/50 | 1/46 | 0/47 | 0/49 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 0/51 | 0/49 | 0/50 | 0/49 | 0/50 | 0/50 | 1/46 | 0/47 | 0/49 |
| Hepatitis acuteHepatobiliary disorders | 0/51 | 0/49 | 0/50 | 0/49 | 0/50 | 0/50 | 1/46 | 0/47 | 0/49 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/51 | 0/49 | 0/50 | 0/49 | 0/50 | 0/50 | 1/46 | 0/47 | 0/49 |
| Alanine aminotransferase increasedInvestigations | 0/51 | 0/49 | 0/50 | 0/49 | 0/50 | 0/50 | 0/46 | 1/47 | 1/49 |
| Transaminases increasedInvestigations | 0/51 | 0/49 | 0/50 | 0/49 | 0/50 | 0/50 | 0/46 | 1/47 | 1/49 |
| Facial paralysisNervous system disorders | 0/51 | 0/49 | 0/50 | 0/49 | 0/50 | 0/50 | 0/46 | 1/47 | 0/49 |
| Varices oesophagealGastrointestinal disorders | 0/51 | 0/49 | 0/50 | 1/49 | 0/50 | 0/50 | 0/46 | 0/47 | 0/49 |
| Event | Delayed Treatment (Baseline to Week 48) | Bulevirtide 2 mg/Day (Baseline to Week 48) | Bulevirtide 10 mg/Day (Baseline to Week 48) | Bulevirtide 2 mg/Day (Baseline to Week 144) | Bulevirtide 10 mg/Day (Baseline to Week 144) | Delayed Treatment/Bulevirtide 10 mg/Day (Week 48 to Week 144) | Bulevirtide 2 mg/Day (After EOT (>Week 144 up to Week 240)) | Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) | Delayed Treatment/Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) |
|---|---|---|---|---|---|---|---|---|---|
| Vitamin D deficiencyMetabolism and nutrition disorders | 13/51 | 7/49 | 7/50 | 22/49 | 19/50 | 14/50 | 6/46 | 7/47 | 7/49 |
| Alanine aminotransferase increasedInvestigations | 4/51 | 2/49 | 3/50 | 5/49 | 4/50 | 0/50 | 19/46 | 11/47 | 18/49 |
| Aspartate aminotransferase increasedInvestigations | 3/51 | 1/49 | 1/50 | 2/49 | 1/50 | 1/50 | 17/46 | 11/47 | 15/49 |
| HeadacheNervous system disorders | 0/51 | 9/49 | 10/50 | 10/49 | 12/50 | 7/50 | 0/46 | 1/47 | 1/49 |
| LeukopeniaBlood and lymphatic system disorders | 10/51 | 7/49 | 5/50 | 10/49 | 9/50 | 7/50 | 2/46 | 4/47 | 5/49 |
| ThrombocytopeniaBlood and lymphatic system disorders | 8/51 | 5/49 | 5/50 | 10/49 | 8/50 | 7/50 | 6/46 | 5/47 | 7/49 |
| NeutropeniaBlood and lymphatic system disorders | 3/51 | 2/49 | 5/50 | 8/49 | 10/50 | 3/50 | 3/46 | 4/47 | 3/49 |
| FatigueGeneral disorders | 1/51 | 5/49 | 7/50 | 7/49 | 9/50 | 3/50 | 0/46 | 5/47 | 4/49 |
| Gamma-glutamyltransferase increasedInvestigations | 1/51 | 0/49 | 2/50 | 1/49 | 3/50 | 2/50 | 8/46 | 4/47 | 3/49 |
| LymphopeniaBlood and lymphatic system disorders | 4/51 | 4/49 | 4/50 | 8/49 | 6/50 | 5/50 | 3/46 | 4/47 | 7/49 |
The Full Analysis Set (FAS) included all participants who were randomized to bulevirtide and took at least 1 dose of bulevirtide and those who were randomized to delayed treatment group.
| Age, Categorical(Participants) | Delayed Treatment/Bulevirtide 10 mg/Day | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 51 | 49 | 50 | 150 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Delayed Treatment/Bulevirtide 10 mg/Day | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day | Total |
|---|---|---|---|---|
| Mean | 41 ± 7.5 | 44 ± 9.0 | 41 ± 8.5 | 42 ± 8.4 |
| Sex: Female, Male(Participants) | Delayed Treatment/Bulevirtide 10 mg/Day | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day | Total |
|---|---|---|---|---|
| Female | 25 | 19 | 20 | 64 |
| Male | 26 | 30 | 30 | 86 |
| Race (NIH/OMB)(Participants) | Delayed Treatment/Bulevirtide 10 mg/Day | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 11 | 8 | 6 | 25 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 |
| White | 40 | 41 | 43 | 124 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Delayed Treatment/Bulevirtide 10 mg/Day | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day | Total |
|---|---|---|---|---|
| Germany | 7 | 6 | 14 | 27 |
| Italy | 7 | 11 | 6 | 24 |
| Russia | 29 | 28 | 28 | 85 |
| Sweden | 8 | 4 | 2 | 14 |
| Hepatitis Delta Virus (HDV) Ribonucleic Acid (RNA)(log10 IU/mL) | Delayed Treatment/Bulevirtide 10 mg/Day | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day | Total |
|---|---|---|---|---|
| Mean | 5.08 ± 1.358 | 5.10 ± 1.194 | 4.96 ± 1.461 | 5.04 ± 1.336 |
| Liver stiffness(kPa) | Delayed Treatment/Bulevirtide 10 mg/Day | Bulevirtide 2 mg/Day | Bulevirtide 10 mg/Day | Total |
|---|---|---|---|---|
| Mean | 15.3 ± 8.95 | 14.0 ± 8.19 | 14.8 ± 9.26 | 14.7 ± 8.77 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Nov 2020, 19 months.
Results were first posted in Oct 2022, 1 year 11 months after primary completion. A results delay was requested in Nov 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bulevirtide